AU2001232032A1 - Benzooxazole derivatives as tnf and pde iv inhibitors - Google Patents

Benzooxazole derivatives as tnf and pde iv inhibitors

Info

Publication number
AU2001232032A1
AU2001232032A1 AU2001232032A AU3203201A AU2001232032A1 AU 2001232032 A1 AU2001232032 A1 AU 2001232032A1 AU 2001232032 A AU2001232032 A AU 2001232032A AU 3203201 A AU3203201 A AU 3203201A AU 2001232032 A1 AU2001232032 A1 AU 2001232032A1
Authority
AU
Australia
Prior art keywords
alkyl
pde
tnf
inhibitors
nr4r5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232032A
Inventor
George Martin Buckley
Richard John Davenport
Hazel Joan Dyke
Alan Haughan Findlay
Hannah Jayne Kendall
Christopher Lowe
John Gary Montana
Catherine Louise Picken
Verity Margaret Sabin
Andrew Sharpe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of AU2001232032A1 publication Critical patent/AU2001232032A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)

Abstract

A compound of the formulawhereinR1 is C1-3 alkyl optionally substituted with one or more fluorines;R2 is C1-6 alkyl, cycloalkyl or NR4R5;R3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C)NR4R5 is a nitrogen-containing heterocyclic ring;R6 is C1-3 alkyl; andR7 and R8, which are the same or different, each represents C1-3 alkyl, halogen, CF3 or CN;or a pharmaceutically-acceptable salt thereof.
AU2001232032A 2000-02-11 2001-02-08 Benzooxazole derivatives as tnf and pde iv inhibitors Abandoned AU2001232032A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0003256.5A GB0003256D0 (en) 2000-02-11 2000-02-11 Heterocyclic compounds and their therapeutic use
GB0003256 2000-02-11
PCT/GB2001/000507 WO2001058896A1 (en) 2000-02-11 2001-02-08 Benzoxazole derivatives as tnf and pde iv inhibitors

Publications (1)

Publication Number Publication Date
AU2001232032A1 true AU2001232032A1 (en) 2001-08-20

Family

ID=9885479

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232032A Abandoned AU2001232032A1 (en) 2000-02-11 2001-02-08 Benzooxazole derivatives as tnf and pde iv inhibitors

Country Status (9)

Country Link
US (1) US6403791B1 (en)
EP (1) EP1261605B1 (en)
JP (1) JP2003522771A (en)
AT (1) ATE282037T1 (en)
AU (1) AU2001232032A1 (en)
DE (1) DE60107056T2 (en)
ES (1) ES2231439T3 (en)
GB (1) GB0003256D0 (en)
WO (1) WO2001058896A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001232340A1 (en) * 2000-02-18 2001-08-27 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
NZ560969A (en) * 2005-02-17 2010-08-27 Albany Molecular Res Inc Benzoxazole carboxamides for treating chemotherapy-induced vomiting and irritable bowel syndrome
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
NZ570625A (en) 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy
WO2008019363A2 (en) * 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5ht3 modulators
EP2061460A2 (en) * 2006-08-07 2009-05-27 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5ht3 modulators
CN101077866B (en) * 2007-05-15 2012-07-11 中国人民解放军第二军医大学 Substituted benzoxazoles antifungal compounds and preparation method thereof
BRPI0811317A2 (en) 2007-08-03 2015-01-27 Summit Corp Plc COMBINATION, PHARMACEUTICAL PACKAGING, KIT OR PACKAGING FOR A PATIENT AGENT, AUXILIARY AGENT, COMPOSITE, USES OF AN AUXILIARY AGENT AND COMPOUND, AND PROCESS FOR PRODUCTION OF A COMBINATION
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
EP2247600A4 (en) * 2008-02-06 2011-09-14 Biomarin Pharm Inc Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp)
WO2015005429A1 (en) * 2013-07-10 2015-01-15 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Novel pde4 inhibitor
CN110114358B (en) * 2016-12-26 2021-12-03 明治制果药业株式会社 Novel compound and pharmacologically acceptable salt thereof
JP6815566B2 (en) * 2018-06-27 2021-01-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 Therapeutic agents for inflammatory, autoimmune, fibrotic, and cancerous diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2802706B2 (en) * 1992-09-28 1998-09-24 富士写真フイルム株式会社 Method for producing heterocyclic compound
RU2170730C2 (en) * 1996-05-20 2001-07-20 Дарвин Дискавери Лимитед Quinoline carboxamides and pharmaceutical composition based on thereof
ATE242234T1 (en) * 1996-11-15 2003-06-15 Darwin Discovery Ltd BICYCLIC ARYLCARBOXAMIDES AND THEIR THERAPEUTIC USE
TW555759B (en) * 1998-06-08 2003-10-01 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use

Also Published As

Publication number Publication date
EP1261605B1 (en) 2004-11-10
DE60107056D1 (en) 2004-12-16
GB0003256D0 (en) 2000-04-05
EP1261605A1 (en) 2002-12-04
WO2001058896A8 (en) 2001-12-20
ATE282037T1 (en) 2004-11-15
WO2001058896A1 (en) 2001-08-16
JP2003522771A (en) 2003-07-29
US6403791B1 (en) 2002-06-11
ES2231439T3 (en) 2005-05-16
DE60107056T2 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
AU2001232032A1 (en) Benzooxazole derivatives as tnf and pde iv inhibitors
NO20054195D0 (en) Isoxazole compounds as inhibitors of heat shock proteins
DK0846686T3 (en) 1-phenylpyrazole derivatives and their use as parasitic agents
EA200500474A1 (en) QUINOLYLPROPYLPIPERIDINE DERIVATIVES AND THEIR APPLICATION AS ANTIMICROBIAL MEANS
MY133572A (en) Gyrase inhibitors and uses thereof
WO2001077107A8 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors
DE60210654D1 (en) ARYL SUBSTITUTED OXAZOLIDINONE WITH ANTIBACTERIAL ACTIVITY
TW200510342A (en) Chemical compounds
DE60226469D1 (en) BIPHENYL CARBOXYL ACID AMID DERIVATIVES AS P38 KINASE INHIBITORS
WO2002064547A3 (en) Isophthalic acid derivatives as matrix metalloproteinase inhibitors
DE602004024988D1 (en) 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS
MXPA04000403A (en) 7-amino triazolopyrimidines for controlling harmful fungi.
TW376385B (en) Watersoluble azole antifungals
NO20072753L (en) 3-Ethylidene hydrazino-substituted heterocyclic compounds as thrombopoietin receptor activators
WO2004052891A8 (en) Heterocyclic compounds, preparation method thereof and use of same as medicaments, such as anti-bacterial medicaments and beta-lactamase inhibitors
FI964463A (en) Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase
RS51126B (en) Process for the preparation of mesylates of piperazine derivatives
MXPA04009421A (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors.
AU2001233838A1 (en) Benzofuran carboxamides and their therapeutic use
WO2008012234A3 (en) Azolylmethyloxiranes, use thereof for controlling plant pathogenic fungi, and agents containing the same
ATE399169T1 (en) IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF INDUCIBLE NO-SYNTHASE
UA80839C2 (en) 1-substituted 4-nitroimidazole compound and process for producing the same
WO2002096886A8 (en) Pyrimidine derivatives
BR0208324A (en) Compounds, compound preparation process and pharmaceutical compositions
EA200500138A1 (en) FUNGICIDAL MIXTURES BASED ON DITIANON